CD69 and neoplasm: In our hands, pDCs activate both Vδ2+ and Vδ2- T cells, provoke major phenotypic changes (upregulation of CD25 and CD69, modulation of immune checkpoint expression) and drive their cytotoxicity toward tumor cells.